<!DOCTYPE html>
<html lang="de">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Behandlungspfad Akute Pankreatitis</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            line-height: 1.6;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            padding: 20px;
            color: #333;
        }

        .container {
            max-width: 1200px;
            margin: 0 auto;
            background: white;
            border-radius: 15px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.3);
            overflow: hidden;
        }

        header {
            background: linear-gradient(135deg, #1e3c72 0%, #2a5298 100%);
            color: white;
            padding: 30px;
            text-align: center;
        }

        header h1 {
            font-size: 2.5em;
            margin-bottom: 10px;
            text-shadow: 2px 2px 4px rgba(0,0,0,0.3);
        }

        .content {
            padding: 30px;
        }

        .phase {
            margin-bottom: 40px;
            border-left: 5px solid #667eea;
            padding-left: 25px;
        }

        .phase h2 {
            color: #1e3c72;
            font-size: 1.8em;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
        }

        .phase-number {
            background: #667eea;
            color: white;
            width: 40px;
            height: 40px;
            border-radius: 50%;
            display: inline-flex;
            align-items: center;
            justify-content: center;
            margin-right: 15px;
            font-weight: bold;
        }

        .subsection {
            margin: 25px 0;
            background: #f8f9fa;
            padding: 20px;
            border-radius: 10px;
            border: 1px solid #e9ecef;
        }

        .subsection h3 {
            color: #2a5298;
            margin-bottom: 15px;
            font-size: 1.4em;
        }

        .flowchart {
            background: white;
            padding: 20px;
            border-radius: 8px;
            margin: 15px 0;
            border: 2px solid #dee2e6;
        }

        .flow-box {
            background: #e7f3ff;
            border: 2px solid #2a5298;
            border-radius: 8px;
            padding: 15px;
            margin: 10px 0;
            text-align: center;
            font-weight: 500;
        }

        .flow-box.diagnosis {
            background: #fff3cd;
            border-color: #ffc107;
        }

        .flow-box.decision {
            background: #d4edda;
            border-color: #28a745;
            position: relative;
        }

        .flow-box.action {
            background: #f8d7da;
            border-color: #dc3545;
        }

        .flow-box.mild {
            background: #d1ecf1;
            border-color: #17a2b8;
        }

        .flow-box.severe {
            background: #f8d7da;
            border-color: #dc3545;
        }

        .flow-arrow {
            text-align: center;
            font-size: 1.5em;
            color: #2a5298;
            margin: 5px 0;
        }

        .flow-split {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 20px;
            margin: 15px 0;
        }

        .flow-split-3 {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 15px;
            margin: 15px 0;
        }

        .checklist {
            background: white;
            padding: 15px;
            border-radius: 8px;
            margin: 10px 0;
        }

        .checklist-item {
            padding: 8px 0;
            display: flex;
            align-items: center;
        }

        .checklist-item::before {
            content: "‚òê";
            font-size: 1.2em;
            margin-right: 10px;
            color: #667eea;
        }

        .warning {
            background: #fff3cd;
            border-left: 4px solid #ffc107;
            padding: 15px;
            margin: 15px 0;
            border-radius: 5px;
        }

        .warning::before {
            content: "‚ö†Ô∏è ";
            font-size: 1.2em;
        }

        .critical {
            background: #f8d7da;
            border-left: 4px solid #dc3545;
            padding: 15px;
            margin: 15px 0;
            border-radius: 5px;
        }

        .critical::before {
            content: "üö® ";
            font-size: 1.2em;
        }

        .success {
            background: #d4edda;
            border-left: 4px solid #28a745;
            padding: 15px;
            margin: 15px 0;
            border-radius: 5px;
        }

        .success::before {
            content: "‚úÖ ";
            font-size: 1.2em;
        }

        .danger {
            background: #f8d7da;
            border-left: 4px solid #dc3545;
            padding: 15px;
            margin: 15px 0;
            border-radius: 5px;
        }

        .danger::before {
            content: "‚ùå ";
            font-size: 1.2em;
        }

        .info-box {
            background: #e7f3ff;
            border-left: 4px solid #2a5298;
            padding: 15px;
            margin: 15px 0;
            border-radius: 5px;
        }

        .lab-table {
            width: 100%;
            border-collapse: collapse;
            margin: 15px 0;
            background: white;
            border-radius: 8px;
            overflow: hidden;
        }

        .lab-table th {
            background: #2a5298;
            color: white;
            padding: 12px;
            text-align: left;
        }

        .lab-table td {
            padding: 10px;
            border-bottom: 1px solid #dee2e6;
        }

        .lab-table tr:hover {
            background: #f8f9fa;
        }

        .timeline {
            display: flex;
            align-items: center;
            justify-content: space-between;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
        }

        .timeline-item {
            text-align: center;
            flex: 1;
            position: relative;
        }

        .timeline-item::after {
            content: "‚Üí";
            position: absolute;
            right: -20px;
            top: 50%;
            transform: translateY(-50%);
            font-size: 1.5em;
            color: #667eea;
        }

        .timeline-item:last-child::after {
            content: "";
        }

        .timeline-dot {
            width: 30px;
            height: 30px;
            background: #667eea;
            border-radius: 50%;
            margin: 0 auto 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            color: white;
            font-weight: bold;
        }

        .dosage {
            background: #e7f3ff;
            padding: 10px 15px;
            border-radius: 5px;
            display: inline-block;
            margin: 5px;
            font-family: 'Courier New', monospace;
            font-weight: bold;
            border: 1px solid #2a5298;
        }

        .open-points {
            background: #fff3cd;
            padding: 25px;
            border-radius: 10px;
            margin-top: 30px;
            border: 2px dashed #ffc107;
        }

        .open-points h2 {
            color: #856404;
            margin-bottom: 15px;
        }

        .open-points ul {
            list-style-type: none;
            padding-left: 0;
        }

        .open-points li {
            padding: 10px;
            margin: 5px 0;
            background: white;
            border-radius: 5px;
            border-left: 4px solid #ffc107;
        }

        .button {
            display: inline-block;
            padding: 10px 20px;
            background: #667eea;
            color: white;
            text-decoration: none;
            border-radius: 5px;
            margin: 5px;
            border: none;
            cursor: pointer;
            transition: background 0.3s;
        }

        .button:hover {
            background: #5568d3;
        }

        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
            }

            .phase {
                page-break-inside: avoid;
            }
        }

        @media (max-width: 768px) {
            .flow-split {
                grid-template-columns: 1fr;
            }

            header h1 {
                font-size: 1.8em;
            }

            .content {
                padding: 15px;
            }
        }

        .indent {
            margin-left: 30px;
        }

        .indent-2 {
            margin-left: 60px;
        }

        ul {
            margin: 10px 0;
            padding-left: 25px;
        }

        li {
            margin: 5px 0;
        }

        strong {
            color: #1e3c72;
        }
    </style>
</head>
<body>
    <div class="container">
        <header>
            <h1>BEHANDLUNGSPFAD AKUTE PANKREATITIS</h1>
            <p>Evidenzbasiertes Protokoll f√ºr die Akutversorgung</p>
        </header>

        <div class="content">

            <!-- PHASE 1: DIAGNOSE -->
            <div class="phase">
                <h2><span class="phase-number">1</span>DIAGNOSE & INITIALES ASSESSMENT (0-6h)</h2>

                <div class="flowchart">
                    <div class="flow-box">
                        Patient mit V.a. Akute Pankreatitis
                    </div>

                    <div class="flow-arrow">‚Üì</div>

                    <div class="flow-box diagnosis">
                        <strong>DIAGNOSEKRITERIEN - mind. 2 von 3</strong>
                    </div>

                    <div class="checklist">
                        <div class="checklist-item">Typische abdominelle Schmerzen</div>
                        <div class="checklist-item">Lipase/Amylase >3x Normwert</div>
                        <div class="checklist-item">Bildgebender Nachweis</div>
                    </div>

                    <div class="flow-arrow">‚Üì</div>

                    <div class="flow-box decision">
                        Diagnose best√§tigt
                    </div>

                    <div class="flow-arrow">‚Üì</div>

                    <div class="subsection">
                        <h3>INITIALES LABOR</h3>
                        <table class="lab-table">
                            <tr>
                                <th>Kategorie</th>
                                <th>Parameter</th>
                            </tr>
                            <tr>
                                <td>Basis</td>
                                <td>BB, Elektrolyte, BUN, Kreatinin, Lipase</td>
                            </tr>
                            <tr>
                                <td>Inflammation</td>
                                <td>CRP, Laktat</td>
                            </tr>
                            <tr>
                                <td>√Ñtiologie</td>
                                <td>Leberwerte (AST, ALT, Bilirubin, Œ≥GT, AP)</td>
                            </tr>
                            <tr>
                                <td>Optional</td>
                                <td>Triglyceride, Kalzium</td>
                            </tr>
                        </table>
                    </div>

                    <div class="flow-arrow">‚Üì</div>

                    <div class="flow-box decision">
                        <strong>SCHWEREGRAD-ASSESSMENT</strong><br>
                        SIRS-Kriterien (‚â•2 von 4)?
                    </div>

                    <div class="checklist">
                        <div class="checklist-item">Temperatur >38¬∞C oder <36¬∞C</div>
                        <div class="checklist-item">Herzfrequenz >90/min</div>
                        <div class="checklist-item">Atemfrequenz >20/min oder PaCO2 <32mmHg</div>
                        <div class="checklist-item">Leukozyten >12.000 oder <4.000/ŒºL</div>
                    </div>

                    <div class="flow-arrow">‚Üì</div>

                    <div class="flow-split">
                        <div class="flow-box mild">
                            <strong>NEIN</strong><br>
                            ‚Üí MILD
                        </div>
                        <div class="flow-box severe">
                            <strong>JA</strong><br>
                            ‚Üí SIRS+
                        </div>
                    </div>

                    <div class="warning">
                        <strong>ZUS√ÑTZLICHE RISIKOFAKTOREN checken:</strong>
                        <ul>
                            <li>Hkt >44%</li>
                            <li>BUN >20 mg/dL (7.1 mmol/L)</li>
                            <li>Kreatinin >1.8 mg/dL (159 Œºmol/L)</li>
                        </ul>
                    </div>
                </div>
            </div>

            <!-- PHASE 2: INITIALE THERAPIE -->
            <div class="phase">
                <h2><span class="phase-number">2</span>INITIALE THERAPIE (0-48h)</h2>

                <div class="subsection">
                    <h3>A) FL√úSSIGKEITSTHERAPIE</h3>

                    <div class="success">
                        <strong>ALLE PATIENTEN: Laktat-Ringer bevorzugt</strong><br>
                        (Ausnahme: Hyperkalz√§mie ‚Üí NaCl 0.9%)
                    </div>

                    <div class="flowchart">
                        <div class="flow-split">
                            <div>
                                <div class="flow-box mild">
                                    <strong>MILD</strong><br><br>
                                    <span class="dosage">1.5 ml/kg/h</span>
                                </div>
                            </div>
                            <div>
                                <div class="flow-box severe">
                                    <strong>SIRS+ / Risiko</strong><br><br>
                                    <span class="dosage">10 ml/kg Bolus</span><br>
                                    (√ºber 30 min)<br>
                                    ‚Üì<br>
                                    <span class="dosage">2.0-2.5 ml/kg/h</span><br>
                                    <small>(nach Komorbidit√§t: Herz, Niere, Alter)</small>
                                </div>
                            </div>
                        </div>

                        <div class="flow-arrow">‚Üì</div>

                        <div class="info-box">
                            <strong>ZIELE - Monitoring alle 4h initial</strong>
                            <div class="checklist">
                                <div class="checklist-item">Herzfrequenz <120/min</div>
                                <div class="checklist-item">MAP 65-85 mmHg</div>
                                <div class="checklist-item">Urinproduktion >0.5-1 ml/kg/h</div>
                                <div class="checklist-item">H√§matokrit-Reduktion (Ziel 35-44%)</div>
                            </div>
                        </div>

                        <div class="flow-arrow">‚Üì</div>

                        <div class="flow-box decision">
                            Ziele erreicht?
                        </div>

                        <div class="flow-split">
                            <div class="flow-box mild">
                                <strong>JA</strong><br>
                                Weiter so
                            </div>
                            <div class="flow-box severe">
                                <strong>NEIN</strong><br>
                                Rate +0.5 ml/kg/h<br>
                                + Oberarzt-Konsil<br>
                                ‚Üì<br>
                                [4h sp√§ter]<br>
                                Besser?<br>
                                ‚Üì NEIN<br>
                                ‚Üí ICU-Verlegung
                            </div>
                        </div>
                    </div>

                    <div class="warning">
                        <strong>48h-CHECK:</strong><br>
                        Fl√ºssigkeitstherapie kritisch √ºberpr√ºfen<br>
                        ‚Üí √úberladung? (√ñdeme, Dyspnoe, O2-Bedarf)<br>
                        ‚Üí Bei Besserung: Reduktion erw√§gen
                    </div>
                </div>

                <div class="subsection">
                    <h3>B) SCHMERZTHERAPIE</h3>

                    <div class="flowchart">
                        <div class="flow-box">
                            SCHMERZASSESSMENT - NRS 0-10
                        </div>

                        <div class="flow-arrow">‚Üì</div>

                        <div class="flow-split">
                            <div>
                                <div class="flow-box mild">
                                    <strong>NRS 1-3 (Mild)</strong><br><br>
                                    <span class="dosage">Paracetamol 1g 4x/d</span><br>
                                    +<br>
                                    <span class="dosage">Ibuprofen 600mg 3x/d</span>
                                </div>
                            </div>
                            <div>
                                <div class="flow-box severe">
                                    <strong>NRS 4-10 (Moderat-Schwer)</strong><br><br>
                                    <span class="dosage">Hydromorphon 2mg i.v. 2x/d</span><br>
                                    +<br>
                                    <span class="dosage">Paracetamol 1g 4x/d</span><br>
                                    <br>
                                    <strong>Bei Bedarf:</strong><br>
                                    Hydromorphon 2-3mg<br>
                                    bis zu 4x/d zus√§tzlich
                                </div>
                            </div>
                        </div>

                        <div class="warning">
                            <strong>NSAID-CHECKBOX vor Gabe:</strong>
                            <div class="checklist">
                                <div class="checklist-item">Kreatinin <1.8?</div>
                                <div class="checklist-item">Keine GI-Blutung/Ulkus?</div>
                                <div class="checklist-item">Thrombos >50.000?</div>
                            </div>
                        </div>

                        <div class="flow-arrow">‚Üì</div>

                        <div class="flow-box decision">
                            24h-Evaluation<br>
                            Schmerz ausreichend kontrolliert (NRS <4)?
                        </div>

                        <div class="flow-arrow">‚Üì NEIN</div>

                        <div class="flow-box action">
                            Hydromorphon-Dosis erh√∂hen auf 4mg<br>
                            Bei weiter unzureichender Kontrolle:<br>
                            ‚Üí Oberarzt/PCA erw√§gen
                        </div>
                    </div>
                </div>
            </div>

            <!-- PHASE 3: MONITORING -->
            <div class="phase">
                <h2><span class="phase-number">3</span>MONITORING & LABOR-KONTROLLEN</h2>

                <div class="subsection">
                    <h3>LABOR-MONITORING erste 72h</h3>

                    <div class="flow-split">
                        <div class="info-box">
                            <strong>MILD (kein SIRS):</strong><br>
                            Alle 24h: BB, Elektrolyte, BUN, Krea, CRP, Laktat
                        </div>
                        <div class="warning">
                            <strong>SIRS+ / Risikopatienten:</strong><br>
                            Alle 12h: BB, Elektrolyte, BUN, Krea, CRP, Laktat
                        </div>
                    </div>

                    <div class="critical">
                        <strong>RED FLAGS - sofortige Reevaluation:</strong>
                        <ul>
                            <li>BUN steigt oder bleibt erh√∂ht (>20 mg/dL)</li>
                            <li>Kreatinin steigt (>1.8 mg/dL)</li>
                            <li>H√§matokrit steigt oder bleibt >44%</li>
                            <li>Persistierendes SIRS >48h</li>
                        </ul>
                        <div class="flow-arrow">‚Üì</div>
                        <strong>MASSNAHMEN:</strong>
                        <ul>
                            <li>Fl√ºssigkeitszufuhr √ºberpr√ºfen/intensivieren</li>
                            <li>Oberarzt informieren</li>
                            <li>Erw√§ge ICU-Verlegung bei Verschlechterung</li>
                        </ul>
                    </div>
                </div>
            </div>

            <!-- PHASE 4: CT-INDIKATIONEN -->
            <div class="phase">
                <h2><span class="phase-number">4</span>CT-INDIKATIONEN</h2>

                <div class="critical">
                    <strong>DRINGEND (innerhalb 24h):</strong>
                    <ul>
                        <li>Diagnostische Unsicherheit (DD: Perforation, Isch√§mie, AAA)</li>
                        <li>Klinische Instabilit√§t trotz ad√§quater Therapie</li>
                        <li><strong>Zeichen von Komplikationen:</strong>
                            <ul>
                                <li>Akutes Abdomen/Peritonismus</li>
                                <li>Hb-Abfall (V.a. Blutung/Pseudoaneurysma)</li>
                                <li>Zunehmende Abdominalspannung (V.a. Kompartment)</li>
                            </ul>
                        </li>
                    </ul>
                </div>

                <div class="info-box">
                    <strong>üìÖ ELEKTIV nach 48-72h bei:</strong>
                    <ul>
                        <li>Keine klinische Besserung trotz Therapie</li>
                        <li>Persistierendes/neu aufgetretenes Fieber</li>
                        <li>Zeichen der Sepsis (V.a. infizierte Nekrose)</li>
                        <li>Persistierende/steigende Entz√ºndungsparameter</li>
                        <li>Zur Schweregradbeurteilung bei moderately severe/severe</li>
                    </ul>
                </div>

                <div class="warning">
                    <strong>WICHTIG:</strong>
                    <ul>
                        <li>Negatives CT vor 72h schlie√üt Nekrose NICHT aus!</li>
                        <li>Optimales Timing f√ºr Nekrose-Nachweis: 72-96h</li>
                        <li>Bei Verschlechterung: Kontroll-CT</li>
                    </ul>
                </div>
            </div>

            <!-- PHASE 5: ERN√ÑHRUNG -->
            <div class="phase">
                <h2><span class="phase-number">5</span>ERN√ÑHRUNG</h2>

                <div class="subsection">
                    <div class="success">
                        <strong>MILD ohne √úbelkeit/Erbrechen/Ileus:</strong>
                        <div class="flowchart">
                            <div class="flow-box">
                                Patient hungrig? (auch <24h m√∂glich!)
                            </div>
                            <div class="flow-arrow">‚Üì</div>
                            <div class="flow-box mild">
                                Low-fat, soft diet<br>
                                <small>(Kartoffeln, Reis, mageres Fleisch, ged√ºnstetes Gem√ºse)</small>
                            </div>
                            <div class="flow-arrow">‚Üì</div>
                            <div class="flow-box decision">
                                Toleriert? ‚Üí Normale Kost
                            </div>
                        </div>

                        <div class="warning">
                            <strong>STOPP bei:</strong>
                            <ul>
                                <li>Erbrechen</li>
                                <li>Zunahme Bauchschmerzen</li>
                                <li>Ileuszeichen</li>
                            </ul>
                            ‚Üí NPO, i.v. Fl√ºssigkeit, Reevaluation nach 24h
                        </div>
                    </div>
                </div>

                <div class="subsection">
                    <div class="danger">
                        <strong>Bei Erbrechen/Ileus/Intoleranz ODER Moderate/Severe Pankreatitis:</strong>
                        <div class="flowchart">
                            <div class="flow-box action">
                                NPO initial
                            </div>
                            <div class="flow-arrow">‚Üì</div>
                            <div class="flow-box">
                                Tag 5-7: Keine orale Nahrung m√∂glich?
                            </div>
                            <div class="flow-arrow">‚Üì</div>
                            <div class="flow-box decision">
                                <strong>ENTERALE ERN√ÑHRUNG</strong><br>
                                Nasogastrale Sonde
                            </div>
                            <div class="flow-arrow">‚Üì</div>
                            <div class="info-box">
                                <strong>Zielrate:</strong> 25 kcal/kg ideales KG/Tag<br>
                                <strong>Mindestens:</strong> 30% = ~8 kcal/kg/Tag<br>
                                <strong>Start:</strong> 25 ml/h polymere Formel<br>
                                Steigerung nach Vertr√§glichkeit
                            </div>
                            <div class="flow-arrow">‚Üì</div>
                            <div class="flow-box">
                                48-72h Evaluation<br>
                                Zielrate erreicht?
                            </div>
                            <div class="flow-arrow">‚Üì NEIN</div>
                            <div class="flow-box action">
                                + Parenterale Ern√§hrung (supplement√§r)
                            </div>
                        </div>

                        <div class="warning">
                            <strong>Stopp-Kriterien enteral:</strong>
                            <ul>
                                <li>Erbrechen</li>
                                <li>Diarrhoe >5x/Tag oder >500ml/24h</li>
                                <li>Zunehmende Schmerzen</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <!-- PHASE 6: ANTIBIOTIKA -->
            <div class="phase">
                <h2><span class="phase-number">6</span>ANTIBIOTIKA-STRATEGIE</h2>

                <div class="danger">
                    <strong>KEINE prophylaktischen Antibiotika!</strong><br>
                    (Auch nicht bei Nekrose)
                </div>

                <div class="success">
                    <strong>Antibiotika NUR bei:</strong>
                </div>

                <div class="subsection">
                    <h3>1) Extrapankreatische Infektion vermutet</h3>
                    <div class="info-box">
                        <strong>Indikationen:</strong> Pneumonie, HWI, Bakteri√§mie<br><br>
                        <strong>Empirisch:</strong> <span class="dosage">Vancomycin + Cefepime</span><br><br>
                        <strong>Wichtig:</strong> Bei Kulturen negativ ‚Üí stoppen!
                    </div>
                </div>

                <div class="subsection">
                    <h3>2) Infizierte Nekrose vermutet</h3>
                    <div class="warning">
                        <strong>Verdacht bei:</strong>
                        <ul>
                            <li>Nach Tag 7-10</li>
                            <li>Fieber, erh√∂hte Leukozyten</li>
                            <li>Keine Besserung</li>
                            <li>Gas in Nekrose im CT?</li>
                        </ul>
                    </div>

                    <div class="info-box">
                        <strong>Empirisch (w√§hle eine Option):</strong>
                        <ul>
                            <li><span class="dosage">Piperacillin/Tazobactam</span></li>
                            <li><span class="dosage">Carbapenem</span></li>
                            <li><span class="dosage">Cefepime + Metronidazol</span></li>
                        </ul>
                        <br>
                        <strong>Management:</strong>
                        <ul>
                            <li>Kulturen abnehmen (Blut)</li>
                            <li>Wenn stabil: konservativ 2-4 Wochen</li>
                            <li>Wenn Verschlechterung trotz AB: Drainage erw√§gen</li>
                        </ul>
                    </div>
                </div>
            </div>

            <!-- OFFENE PUNKTE -->
            <div class="open-points">
                <h2>üìã OFFENE PUNKTE F√úR N√ÑCHSTE PHASE</h2>

                <ul>
                    <li><strong>1. GALLENSTEIN-PANKREATITIS - Management</strong>
                        <ul>
                            <li>ERCP-Indikationen & Timing</li>
                            <li>Cholezystektomie-Timing</li>
                        </ul>
                    </li>
                    <li><strong>2. KOMPLIKATIONEN</strong>
                        <ul>
                            <li>Infizierte Nekrose (Drainage/Nekrosektomie)</li>
                            <li>Splanchnikus-Venenthrombose</li>
                            <li>Pseudoaneurysma</li>
                            <li>Abdominal Compartment Syndrome</li>
                        </ul>
                    </li>
                    <li><strong>3. ENTLASSKRITERIEN & NACHSORGE</strong></li>
                </ul>

                <div style="text-align: center; margin-top: 20px;">
                    <button class="button" onclick="alert('Gallenstein-Management wird als n√§chstes entwickelt')">Gallenstein-Management</button>
                    <button class="button" onclick="alert('Komplikationen werden als n√§chstes entwickelt')">Komplikationen</button>
                    <button class="button" onclick="alert('Entlasskriterien werden als n√§chstes entwickelt')">Entlasskriterien</button>
                </div>
            </div>

            <!-- FOOTER -->
            <div style="text-align: center; padding: 30px; background: #f8f9fa; margin-top: 40px; border-radius: 10px;">
                <p><strong>Hinweis:</strong> Dieses Protokoll basiert auf aktuellen evidenzbasierten Leitlinien.</p>
                <p>Bei Fragen oder Unsicherheiten konsultieren Sie einen Oberarzt oder Facharzt.</p>
                <p style="margin-top: 20px; color: #6c757d;">
                    <small>Letzte Aktualisierung: Oktober 2025</small>
                </p>
            </div>
        </div>
    </div>
</body>
</html>